SOTIO Advances SOT106 with FDA Designations
News related to:SOTIO Biotech · 3 min read
PRAGUE and BASEL, Switzerland and BOSTON, Sept. 23, 2026 /CourierPR/ -- SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) and Fast Track Designation for the treatment of osteosarcoma, supporting its planned clinical development as a potentially best-in-class investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes. The company’s two lead ADC programs, SOT106 and SOT109, are potential best-in-class therapies designed to rapidly advance to clinical proof of concept.
The Orphan Drug Designation underscores the promise of SOT106 and strengthens the program’s potential path to patients. SOT106 combines SOTIO’s proprietary LRRC15-targeting antibody with LigaChem Biosciences’ ConjuAll™ site-specific conjugation and beta-glucuronidase-cleavable linker, which is designed to remain stable in circulation and release the payload selectively within the tumor.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) and Fast Track Designation for the treatment of osteosarcoma, supporting its planned clinical development as a potentially best-in-class investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes.
The Fast Track Designation underscores the promise of SOT106 and strengthens the program’s potential path to patients. SOT106 combines SOTIO’s proprietary LRRC15-targeting antibody with LigaChem Biosciences’ ConjuAll™ site-specific conjugation and beta-glucuronidase-cleavable linker, which is designed to remain stable in circulation and release the payload selectively within the tumor.
The Fast Track Designation to be initiated in 2026 underscores the promise of SOT106 and strengthens the program’s potential path to patients. SOT106 combines SOTIO’s proprietary LRRC15-targeting antibody with LigaChem Biosciences’ ConjuAll™ site-specific conjugation and beta-glucuronidase-cleavable linker, which is designed to remain stable in circulation and release the payload selectively within the tumor.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) and Fast Track Designation for the treatment of osteosarcoma, supporting its planned clinical development as a potentially best-in-class investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes. The company’s two lead ADC programs, SOT106 and SOT109, are potential best-in-class therapies designed to rapidly advance to clinical proof of concept.
The Orphan Drug Designation underscores the promise of SOT106 and strengthens the program’s potential path to patients. SOT106 combines SOTIO’s proprietary LRRC15-targeting antibody with LigaChem Biosciences’ ConjuAll™ site-specific conjugation and beta-glucuronidase-cleavable linker, which is designed to remain stable in circulation and release the payload selectively within the tumor.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) and Fast Track Designation for the treatment of osteosarcoma, supporting its planned clinical development as a potentially best-in-class investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes. The company’s two lead ADC programs, SOT106 and SOT109, are potential best-in-class therapies designed to rapidly advance to clinical proof of concept.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) and Fast Track Designation for the treatment of osteosarcoma, supporting its planned clinical development as a potentially best-in-class investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes. The company’s two lead ADC programs, SOT106 and SOT109, are potential best-in-class therapies designed to rapidly advance to clinical proof of concept.
The Fast Track Designation underscores the promise of SOT106 and strengthens the program’s potential path to patients. SOT106 combines SOTIO’s proprietary LRRC15-targeting antibody with LigaChem Biosciences’ ConjuAll™ site-specific conjugation and beta-glucuronidase-cleavable linker, which is designed to remain stable in circulation and release the payload selectively within the tumor.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced that the U.S. Food and Drug Administration has granted SOT106 Orphan Drug Designation for the treatment of soft tissue sarcoma (STS) and Fast Track Designation for the treatment of osteosarcoma, supporting its planned clinical development as a potentially best-in-class investigational antibody-drug conjugate (ADC) across multiple sarcoma subtypes.